Un sitio oficial del Gobierno de los Estados Unidos
Así es como usted puede verificarlo
El .gov significa que es oficial.
Los sitios web del gobierno federal siempre usan un dominio .gov o .mil. Antes de compartir información confidencial en línea, asegúrese de estar en un sitio .gov o .mil.
Este sitio es seguro.
El https:// medios todos los datos transmitidos son cifrados - en otras palabras, cualquier información o el historial de navegación que proporcione se transmite de forma segura.
Legal Library: Search
The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
In July 2020, the Federal Trade Commission filed a complaint in federal court against the California-based marketers and promoters of bogus treatments for serious medical conditions. The defendants are two corporations headquartered in Porterville, California, and two of their executives: Huu Tieu, president and CEO of both companies; and Stephen Meis, Medical Director and board member of Golden Sunrise Nutraceutical. The complaint alleged that defendants have promoted and sold a variety of products through "plans of care" ranging in price from $23,000 to $200,000, which falsely claim to treat or cure COVID-19, cancer, Parkinson's disease, etc. On June 14, 2021, the FTC announced a proposed order barring the defendants from making bogus health claims. In January 2024, the FTC announced the process defrauded consumers can use to seek refunds.
The Federal Trade Commission has sued Facebook, alleging that the company is illegally maintaining its personal social networking monopoly through a years-long course of anticompetitive conduct. The complaint alleges that Facebook has engaged in a systematic strategy—including its 2012 acquisition of up-and-coming rival Instagram, its 2014 acquisition of the mobile messaging app WhatsApp, and the imposition of anticompetitive conditions on software developers—to eliminate threats to its monopoly. The Commission vote to authorize staff to file for a permanent injunction and other equitable relief in the U.S. District Court for the District of Columbia was 3-2. Commissioners Noah Joshua Phillips and Christine S. Wilson voted no.
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
The Federal Trade Commission issued an administrative complaint to block medical device supplier Edwards Lifesciences Corp.’s (Edwards) proposed acquisition of JenaValve Technology, Inc. (JenaValve) due to concerns that the acquisition would limit patient access to lifesaving medical devices used to treat a potentially fatal heart condition. On January 9, 2026, after a six-day trial, the U.S. District Court for the District of Columbia granted the FTC’s request for a preliminary injunction to temporarily prevent Edwards from acquiring JenaValve.
To settle Federal Trade Commission charges that it engaged in deceptive and unfair practices, Dun & Bradstreet (D&B) has agreed to an order requiring substantial changes in the firm’s operations that will benefit small- and mid-sized businesses. Under the proposed order, D&B will also provide refunds to certain businesses that purchased the company’s products in the belief that using the products would improve their business credit scores and ratings.
